Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeRes: Temozolomide in Relapsed SCLC with MGMT Methylation
NCT02477813Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jan 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in small cell lung cancer (SCLC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Jan 2015; status: terminated.
02
Drugs
temozolomide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02477813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477813.